Bora Gürer1, Ramazan Kahveci2, Emre Cemal Gökçe3, Huseyin Ozevren2, Erhan Turkoglu4, Aysun Gökçe5. 1. Department of Neurosurgery, Ministry of Health, Fatih Sultan Mehmet Education and Research Hospital, 34752, Ataşehir, Istanbul, Turkey. Electronic address: boragurer@gmail.com. 2. Department of Neurosurgery, Ministry of Health, Kirikkale Yüksek Ihtisas Hospital, Baglarbasi mh. Lokman Hekim cd., Kirikkale, Turkey. 3. Department of Neurosurgery, Faculty of Medicine, Turgut Ozal University, Ayvali mh., Gazze cd., No:7 Etlik, Kecioren, Ankara, Turkey. 4. Department of Neurosurgery, Ministry of Health, Diskapi Yildirim Beyazit Education and Research Hospital, Irfan Bastug cd., Diskapi, Ankara, Turkey. 5. Department of Pathology, Ministry of Health, Diskapi Yildirim Beyazit Education and Research Hospital, Irfan Bastug cd., Diskapi, Ankara, Turkey.
Abstract
BACKGROUND CONTEXT: Epidural fibrosis is a major challenge in spine surgery, with some patients having recurrent symptoms secondary to excessive formation of scar tissue resulting in neurologic compression. One of the most important factors initiating the epidural fibrosis is assumed to be the transforming growth factor-1β (TGF-1β). Rosuvastatin (ROS) has shown to demonstrate preventive effects over fibrosis via inhibiting the TGF-1β. PURPOSE: We hypothesized that ROS might have preventive effects over epidural fibrosis through the inhibition of TGF-1β pathways. STUDY DESIGN: Experimental animal study. METHODS: Forty-eight adult male Wistar Albino rats were equally and randomly divided into four groups (laminectomy, spongostan, topical ROS, and systemic ROS). Laminectomy was performed at the L3 level in all rats. Four weeks later, the extent of epidural fibrosis was assessed both macroscopically and histopathologically. RESULTS: Our data revealed that topical application and systemic administration of ROS both were effective in reducing epidural fibrosis formation. Furthermore, the systemic administration of ROS yielded better results than topical application. CONCLUSIONS: Both topical application and systemic administration of ROS show meaningful preventive effects over epidural fibrosis through multiple mechanisms. The results of our study provide the first experimental evidence of the preventive effects of ROS over epidural fibrosis.
BACKGROUND CONTEXT: Epidural fibrosis is a major challenge in spine surgery, with some patients having recurrent symptoms secondary to excessive formation of scar tissue resulting in neurologic compression. One of the most important factors initiating the epidural fibrosis is assumed to be the transforming growth factor-1β (TGF-1β). Rosuvastatin (ROS) has shown to demonstrate preventive effects over fibrosis via inhibiting the TGF-1β. PURPOSE: We hypothesized that ROS might have preventive effects over epidural fibrosis through the inhibition of TGF-1β pathways. STUDY DESIGN: Experimental animal study. METHODS: Forty-eight adult male Wistar Albino rats were equally and randomly divided into four groups (laminectomy, spongostan, topical ROS, and systemic ROS). Laminectomy was performed at the L3 level in all rats. Four weeks later, the extent of epidural fibrosis was assessed both macroscopically and histopathologically. RESULTS: Our data revealed that topical application and systemic administration of ROS both were effective in reducing epidural fibrosis formation. Furthermore, the systemic administration of ROS yielded better results than topical application. CONCLUSIONS: Both topical application and systemic administration of ROS show meaningful preventive effects over epidural fibrosis through multiple mechanisms. The results of our study provide the first experimental evidence of the preventive effects of ROS over epidural fibrosis.
Authors: David Reigada; Rosa María Navarro-Ruiz; Marcos Javier Caballero-López; Ángela Del Águila; Teresa Muñoz-Galdeano; Rodrigo M Maza; Manuel Nieto-Díaz Journal: Purinergic Signal Date: 2016-10-19 Impact factor: 3.765
Authors: Juan N Albiñana-Cunningham; Purificación Ripalda-Cemboráin; Tania Labiano; José I Echeveste; Froilán Granero-Moltó; Matías Alfonso-Olmos Journal: J Orthop Surg Res Date: 2018-04-05 Impact factor: 2.359
Authors: Haixiao Wu; Alexey V Germanov; Galina L Goryaeva; Alexander N Yachmenev; Dmitriy I Gordienko; Victor V Kuzin; Alexander V Skoroglyadov Journal: Med Sci Monit Date: 2016-04-26